Stock Financial Ratios, Dividends, Split History

PATK / Patrick Industries, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)1,469.21
Enterprise Value ($M)1,898.05
Book Value ($M)405.78
Book Value / Share16.38
Price / Book3.62
NCAV ($M)-263.07
NCAV / Share-10.62
Price / NCAV-5.58
Share Statistics
Common Stock Shares Outstanding 25,329,857
Weighted Average Number Diluted Shares Outstanding Adjustment 413,000
Weighted Average Number Of Diluted Shares Outstanding 24,643,000
Weighted Average Number Of Shares Outstanding Basic 24,230,000
Common Shares Outstanding 25,471,135
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.12
Return on Assets (ROA)0.16
Return on Equity (ROE)0.46
Balance Sheet (mrq) ($M)
Quick Ratio0.86
Current Ratio2.01
Income Statement (mra) ($M)
Sales Revenue Goods Net1,635,653,000.00
Sales Revenue Net1,635,653,000.00
Operating Income121.90
Net Income85.72
Earnings Per Share Diluted3.48
Earnings Per Share Basic3.54
Cash Flow Statement (mra) ($M)
Cash From Operations99.90
Cash from Investing-273.14
Cash from Financing-273.14
Identifiers and Descriptors
Central Index Key (CIK)76605
Related CUSIPS

Split History

Stock splits are used by Patrick Industries, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

8h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

9h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Patrick Industries Inc. Is A Buy

2018-07-13 seekingalpha
Although the shares have been on a tear the past year, I think there's still room to grow because the company is growing free cash very rapidly.

Quarterly Performance Review - Q2 2018

2018-07-04 seekingalpha
As I regularly research and present interesting investment ideas, I decided to compose a brief performance review of my model research portfolio every quarter from Q1/2017 on. (2-0)

KBR Secures DuPont Safety & Construction Project Contract

2018-06-27 zacks
KBR, Inc. (KBR - Free Report) secured a contract from DuPont Safety & Construction — a business unit of DowDuPont Specialty Products Division — to expand capacity for the manufacture of Tyvek nonwoven materials. DuPont Safety & Construction plans to invest more than $400 million to expand capacity for the production of Tyvek nonwoven materials at its facility in Luxembourg. Terms of Contract KBR will be providing project management, engineering, procurement and construction management services for DuPont Safety & Construction’s third operating line at the site. (2-0)

Martin Marietta (MLM) Buys CRH's Sand & Gravel Division

2018-06-26 zacks
Martin Marietta Materials, Inc. (MLM - Free Report) acquired CRH America’s Mallard Sand & Gravel business in Omaha, which is in line with the strategy to strengthen the aggregates business. CRH Americas is a leading supplier of aggregates, cement, asphalt, ready mixed concrete as well as paving and construction services in North America. Buyout Benefits With the inclusion of the business, Martin Marietta will acquire sand and gravel operations along with a permitted greenfield site. (8-0)

The Zacks Analyst Blog Highlights: Nike, Morgan Stanley, FedEx, TOTAL and ArcelorMittal

2018-06-22 zacks
Chicago, IL –June 22, 2018 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Nike (NKE - Free Report) , Morgan Stanley (MS - Free Report) , FedEx (FDX - Free Report) , TOTAL S.A. (TOT - Free Report) and ArcelorMittal (MT - Free Report) . (30-0)

CUSIP: 703343103